The "Drug Overview: Invega Sustenna/Invega Trinza" report has been added to ResearchAndMarkets.com's offering. Invega Sustenna and Invega Trinza (paliperidone palmitate; Johnson & Johnson) are ...
The Food and Drug Administration has approved Invega Hafyera ™ (paliperidone palmitate), an every 6-month injection, for the treatment of schizophrenia in adults. Invega Hafyera is a long-acting ...
Johnson & Johnson has had little trouble keeping sales from its Invega portfolio of long-acting antipsychotic injectables in the billions. Now, it's angling for approval of an even more durable ...
TITUSVILLE, N.J., Sept. 1, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical ...
Invega Hafyera (paliperidone palmitate) is a prescription drug that’s used to treat schizophrenia. It’s given as an injection into your muscle by your doctor or another healthcare professional. Invega ...
The FINANCIAL — A study published in The Journal of Clinical Psychiatry shows that long-acting INVEGA SUSTENNA (paliperidone palmitate) was effective six months longer than commonly prescribed oral ...
Invega Hafyera is the third drug in Johnson & Johnson's Invega franchise to be approved, joining the monthly Invega Sustenna and quarterly Invega Trinza. Based on Invega Hafyera's similar efficacy to ...
The word "blockbuster" gets thrown around quite a bit when it comes to prescription drugs. But now, the blockbuster status of Invega Sustenna, an injectible antipsychotic drug used to treat ...
(RTTNews) - Janssen Pharmaceutical, Inc., wholly-owned by Johnson & Johnson (JNJ), announced Wednesday that the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results